Search Results - "Aedo, Socrates"

Refine Results
  1. 1

    Health screening of middle-aged women: what factors impact longevity? by Blümel, Juan E., Aedo, Sócrates, Murray, Nigel, Vallejo, María S., Chedraui, Peter

    Published in Menopause (New York, N.Y.) (01-09-2022)
    “…The aim of this study was to measure the impact of different risk factors in middle-aged women on longevity evaluated after three decades of an initial health…”
    Get full text
    Journal Article
  2. 2

    Epigenetic Signatures at the RUNX2‐P1 and Sp7 Gene Promoters Control Osteogenic Lineage Commitment of Umbilical Cord‐Derived Mesenchymal Stem Cells by Sepulveda, Hugo, Aguilar, Rodrigo, Prieto, Catalina P., Bustos, Francisco, Aedo, Sócrates, Lattus, José, van Zundert, Brigitte, Palma, Veronica, Montecino, Martin

    Published in Journal of cellular physiology (01-09-2017)
    “…Wharton's Jelly mesenchymal stem cells (WJ‐MSCs) are an attractive potential source of multipotent stem cells for bone tissue replacement therapies. However,…”
    Get full text
    Journal Article
  3. 3

    Risk factors for the development of osteoarthritis in middle-aged women by Blümel, Juan E, Aedo, Sócrates, Arteaga, Eugenio, Vallejo, María S, Chedraui, Peter

    Published in Revista medíca de Chile (01-01-2022)
    “…BACKGROUNDOsteoarthritis (OA) is a health problem affecting millions of individuals worldwide. AIMTo evaluate risk factors for hip and knee osteoarthritis (OA)…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone by Murray, Nigel P, Aedo, Socrates, Villalon, Ricardo, Albarran, Vidal, Orrego, Shenda, Guzman, Eghon

    Published in Ecancermedicalscience (08-10-2020)
    “…Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We…”
    Get full text
    Journal Article
  9. 9

    Netrin-1 acts as a non-canonical angiogenic factor produced by human Wharton's jelly mesenchymal stem cells (WJ-MSC) by Prieto, Catalina P, Ortiz, María Carolina, Villanueva, Andrea, Villarroel, Cynthia, Edwards, Sandra S, Elliott, Matías, Lattus, José, Aedo, Sócrates, Meza, Daniel, Lois, Pablo, Palma, Verónica

    Published in Stem cell research & therapy (28-02-2017)
    “…Angiogenesis, the process in which new blood vessels are formed from preexisting ones, is highly dependent on the presence of classical angiogenic factors…”
    Get full text
    Journal Article
  10. 10

    The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance by Murray, Nigel P, Reyes, Eduardo, Fuentealba, Cynthia, Aedo, Socrates, Jacob, Omar

    Published in Ecancermedicalscience (10-01-2017)
    “…Active surveillance (AS) is a considered treatment option for men with low or very low-risk prostate cancer. However, on repeat biopsy some 25% were upgraded…”
    Get full text
    Journal Article
  11. 11

    The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy by Murray, Nigel P, Aedo, Socrates, Fuentealba, Cynthia, Reyes, Eduardo, Salazar, Anibal, Guzman, Eghon, Orrego, Shenda

    Published in Ecancermedicalscience (2020)
    “…The objective of this study was to compare the CAPRA-S score (based on clinicopathological findings) and the subtypes of minimal residual disease (MRD) (based…”
    Get full text
    Journal Article
  12. 12

    Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy by Murray, Nigel P, Aedo, Socrates, Fuentealba, Cynthia, Reyes, Eduardo, Salazar, Anibal, Lopez, Marco Antonio, Minzer, Simona, Orrego, Shenda, Guzman, Eghon

    Published in Ecancermedicalscience (06-06-2019)
    “…The Gleason score is a strong prognostic factor for treatment failure in pathologically organ-confined prostate cancer (pT2) treated by radical prostatectomy…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer. by Murray, Nigel P, Aedo, Sócrates, Fuentealba, Cynthia, Salazar, Aníbal, Reyes, Eduardo, Lopez, Marco Antonio, Minzer, Simona

    Published in Archivos españoles de urología (01-12-2019)
    “…Minimal residual disease (MRD) is that which persists after curative treatment for prostate cancer. It has the potential to grow and cause metastasis. The…”
    Get more information
    Journal Article
  16. 16
  17. 17

    The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy by Murray, Nigel P, Aedo, Socrates, Fuentealba, Cynthia, Reyes, Eduardo, Salazar, Anibal, Guzman, Eghon, Orrego, Shenda

    Published in Ecancermedicalscience (12-05-2020)
    “…External beam radiotherapy is a treatment option for clinically localised prostate cancer; however, some 15% of patients will undergo treatment failure within…”
    Get full text
    Journal Article
  18. 18

    Womenʼs Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks by Aedo, Sócrates, Cavada, Gabriel, Blümel, Juan E, Chedraui, Peter, Fica, Juan, Barriga, Patricio, Brantes, Sergio, Irribarra, Cristina, Vallejo, María, Campodónico, Ítalo

    Published in Menopause (New York, N.Y.) (01-12-2015)
    “…OBJECTIVE:This study aims to determine time differences (differences in restricted mean survival times [RMSTs]) in the onset of invasive breast cancer,…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Quality of life in climacteric Chilean women treated with low-dose estrogen by Aedo, Sócrates, Schiattino, Irene, Cavada, Gabriel, Porcile, Arnaldo

    Published in Maturitas (20-11-2008)
    “…Abstract Objectives To evaluate the impact of low-dose oral estrogen therapy on the health-related quality of life (HRQoL) in 45–64-year-old women from the…”
    Get full text
    Journal Article